Hyperphosphatemia is common in kidney failure treated by dialysis and is associated with increased risk for mortality.1 Because dietary phosphate restriction is challenging and often insufficient to lower serum phosphorus levels and current dialysis practices do not efficiently lower phosphorus levels, phosphate binders are the principal treatment for hyperphosphatemia among maintenance dialysis patients.